Haitao Ma

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 529 citations

Medicine, Oncology, Pharmacology +10

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Shun Lü, Wei Zhang, Lin Wu et al. · JAMA · 2024 · 336 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial

Dongsheng Yue, Shidong Xu, Qun Wang et al. · The Lancet Respiratory Medicine · 2018 · 293 citations

Medicine, Oncology, Pharmacology +13

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Qun Wang, Weimin Mao, Lin Wu et al. · Journal of Clinical Oncology · 2020 · 279 citations · Full text

Medicine, Oncology, Pharmacology +15

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

Yanhui Chen, Quanxing Liu, Zhiming Chen et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 109 citations · Full text

Medicine, Cancer Biology, Oncology +17